期刊名称：EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
 期刊简介(About the journal)
投稿须知(Instructions to Authors)
编辑部信息(Editorial Board)
About the journal
The European Journal of Pharmaceutical Sciences is the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS). The journal publishes research reports, review articles and scientific commentaries on all aspects of the pharmaceutical sciences with strong emphasis on originality and scientific quality. The Editors welcome articles in this multidisciplinary field, ranging from drug discovery, over drug delivery to drug development. More specifically, the Journal publishes reports in medicinal chemistry, pharmacology, drug absorption and metabolism, pharmacokinetics and pharmacodynamics, pharmaceutical and biomedical analysis, drug delivery including gene delivery, drug targeting, pharmaceutical technology, pharmaceutical biotechnology and clinical drug evaluation. Scientific commentaries and review articles are generally by invitation only or by consent of the Editors. Proceedings of scientific meetings may be published as special issues or supplements to the Journal. Manuscripts submitted to the Journal are only accepted on the understanding that (a) they are subject to editorial review (generally by two independent referees); (b) they have not been, and will not be, published in whole or in part in any other journal; (c) the recommendations of the Declarations of Helsinki and Tokyo, for humans, and the European Community guidelines as accepted principles for the use of experimental animals have been adhered to.
Audience
Pharmaceutical and Biopharmaceutical Scientists, Medicinal Chemists, Pharmacologists, Analytical Chemists, Clinical Pharmacologists, Pharmaceutical Engineers
Abstracting / Indexing
- BIOSIS
- Beilstein Database
- CAB Abstracts
- Chemical Abstracts
- Current Contents/Life Sciences
- EMBASE
|
- International Pharmaceutical Abstracts
- Medline
- Natural Products Update/Royal Society of Chemistry
- S.E.F. Editoriale
- Science Citation Index
|
Instructions to Authors
1.1. Manuscripts
Authors are requested to submit the original manuscript and 3 copies, complete with 4 sets of figures and tables together with the electronic version (see 1.3. Electronic manuscripts) to the following address:
Professor Arto Urtti, European Journal of Pharmaceutical Sciences, Department of Pharmaceutics, University of Kuopio, P.O. Box 1627, FIN-70211 Kuopio, Finland (Tel.: +358-17-162480; Fax: +358-17-162252, E-mail: ejps@uku.fi).
Please include full contact information - corresponding author name, e-mail address, telephone and fax numbers, and full postal address.
Only manuscripts written in English should be submitted. Manuscripts submitted by facsimile transmission will not be considered.
Manuscripts submitted to the journal are accepted on the understanding that: (1) they are subject to editorial review, (2) they have not been and will not be published in whole or in part in any other journal and (3) the recommendations of the Declarations of Helsinki and Tokyo, for humans, and the European Community guidelines as accepted principles for the use of experimental animals, have been adhered to. The European Journal of Pharmaceutical Sciences will, therefore, only consider manuscripts that describe experiments which have been carried out under approval of an institutional or local ethics committee. Authors must state in the manuscript that the protocol complies with the particular recommendation and that approval of their protocols was obtained.
1.2. Format
Manuscripts should be printed with double spacing (at least 6 mm between lines) and with wide margins (not more than 26 lines per page). The possibility that accepted manuscripts will be processed by electronic scanning makes it essential that the typing/printing be of the highest quality. A laser-type or similar quality printer or a high-quality typewriter with a black carbon ribbon should be used to ensure proper contrast for the original. A standard, at least 12-point (0.0138 inch), type face, neither distorted nor reduced or enlarged, is to be used. Manuscripts printed with low-quality printers will be returned for retyping with an acceptable type face.
Webster's New International Dictionary or the Oxford English Dictionary should be consulted for spelling. Latin plurals should not be used if the English equivalent has become the accepted form, e.g., formulas not formulae. Use of hyphens, capital letters, numbers written or spelled out (e.g., 8 or eight) should be consistent throughout the manuscript. Words at the end of a line should not be divided.
1.3. Electronic manuscripts
The original manuscript must be submitted on disk, together with four identical printed hard copies. Please save the manuscript (title page, abstract, text, references, figure legends and tables) into a single file. Save the figures as separate files. In addition, always save the title page and the abstract as a separate file called TITLEABS. It is important that the file on disk and the printed copies be identical.
Electronic files can be submitted on floppy disks, ZIP/JAZ disks, or CD-ROM. Ensure that the letter "l" and digit "1" (also letter "O" and digit "0") have been used properly, and format your article (tabs, indents, etc.) consistently. Characters not available on your word processor (Greek letters, mathematical symbols, etc.) should not be left open but indicated by a unique code (e.g., gralpha, @, #, etc., for the Greek letter ). Such codes should be used consistently throughout the entire text. Please make a list of such codes and provide a key. Do not allow your word processor to introduce word splits and do not use a 'justified' layout. Please adhere strictly to the general instructions on style/arrangement and, in particular, the reference style of the journal. It is very important that you save your file in the word processor format. If your word processor features the option to save files "in flat ASCII", please do not use it. Format your disk correctly and ensure that only the relevant file (one complete article only) is on the disk. Also, specify the type of computer and word processing package used, label the disk with your name and the name of the file on the disk.
After final acceptance for publication, your revised manuscript must be submitted on disk, together with two identical printed hard copies, to the Editor-in-Chief. It is important that the file on disk and the printed copies be identical.
Additional instructions on how to prepare your manuscript can be found at: http://authors.elsevier.com/quickguide . More in-depth guidelines for submitting artwork/illustrations can be found at: http://authors.elsevier.com/artwork .
1.4. Abbreviations
Abbreviations are a hindrance for the reader. Use as few abbreviations as possible and write out names of compounds, receptors, etc., in full throughout the text of the manuscript, with the exceptions given below. Unnecessary and nonsense abbreviations are not allowed. Generic names should not be abbreviated. As an example, AMP, HAL, HIST, RAMH, TAM, SST, for amphetamine, haloperidol, histamine, (R)- -methylhistamine, tamoxifen, somatostatin, are not accepted. Abbreviations which have come to replace the full term (e.g., GABA, DOPA, PDGF, 5-HT, for -aminobutyric acid, 3,4-dihydroxyphenylalanine, PDGF, 5-hydroxytryptamine) may be used, provided the term is spelled out in the abstract and in the body of the manuscript the first time the abbreviation is used. Unwieldy chemical names may be abbreviated. As an example, 8-OH-DPAT, DOI, DTG, BAPTA, for 8-hydroxy-2-(di-n-propylamino)tetralin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane, 1,3-di(2-tolyl)-guanidine, 1,2-bis(o-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, are acceptable; however, the full chemical name should be given once in the body of the manuscript and in the abstract, followed in both cases by the abbreviation. Code names may be used, but the full chemical name should be given in the text and in the abstract. Authors not conforming to these demands may have their manuscripts returned for correction with delayed publication as a result.
Some abbreviations may be used without definition:
border=1>
ADP,CDP, GDP, IDP 5'-pyrophosphates of adenosine
UDP cytidine, guanosine, inosine, uridine
AMP etc. adenosine 5'-monophosphate etc.
ADP etc. adenosine 5'-diphosphate etc.
ATP etc. adenosine 5'-triphosphate etc.
CM-cellulose carboxymethylcellulose
CoA and acetyl-CoA coenzyme A and its acyl derivatives
DEAE-cellulose O-(diethylaminoethyl)-cellulose
DNA deoxyribonucleic acid
EGTA ethylene glycol-bis(-aminoethyl ether)N,N,N',N'-tetraacetic acid
FAD flavin-adenine dinucleotide
FMN flavin mononucleotide
GSH, GSSG glutathione, reduced and oxidized
Hepes 4-(2-hydroxyethyl)-1-piperazine-ethanesulphonic acid
NAD nicotinamide-adenine dinucleotide
NADP nicotinamide-adenine dinucleotide phosphate
NMN nicotinamide mononucleotide
Pi, PPi orthophosphate, pyrophosphate
RNA ribonucleic acid
Tris 2-amino-2-hydroxymethylpropane-1,3-diol
Two alternative conventions are currently in use in some cases. For example, for the phosphoinositides there are both the abbreviations recommended by the IUPAC-IUB and those of the Chilton Convention (e.g., PtdIns(4,5)P2 vs. PIP 2for phosphatidylinositol 4,5-biphosphate). The journal will accept either of these forms but not their combination.
Abbreviations of units of measurements and other terms are as follows:
Units of mass
border=1>
kilogram kg
gram g
milligram mg
microgram g
nanogram ng
mole (gram-molecule) mol
millimole mmol
micromole mol
nanomole nmol
picomole pmol
femtomole fmol
equivalent eq
Units of time
border=1>
hour h
minute min
second s
millisecond ms
microsecond s
Units of volume
border=1>
litre l
millilitre ml
microlitre l
Units of length
border=1>
metre m
centimetre cm
millimetre mm
micrometre m
nanometre nm
Units of concentration
border=1>
molar (mol/l) M
millimolar mM
micromolar M
nanomolar nM
picomolar pM
Units of heat, energy, electricity
border=1>
joule J
degree Celsius (centigrade) C
coulomb C
ampere A
volt V
ohm
siemens S
Units of radiation
border=1>
curie Ci
counts per minute cpm
disintegrations per minute dpm
becquerel Bq
Miscellaneous
border=1>
gravity g
dissociation constant Kd
median doses LD50, ED50
probability P
routes of drug administration i.v., i.p., s.c., i.m.
square centimetre cm2
standard deviation S.D.
standard error of the mean S.E.M.
Svedberg unit of sedimentation coefficient S
Hill coefficient nH
The isotope mass number should appear before the atomic symbol, e.g., [3H]noradrenaline, [14C]choline. Ions should be written: Fe3+, Ca2+, Mg2+. The term absorbance (A) is preferred to extinction or optical density. For abbreviations not included in this list consult: Units, Symbols and Abbreviations, A Guide for Biological and Medical Authors and Editors, 1994 (The Royal Society of Medicine, London), ISBN 0-905958-78-0, or Scientific Style and Format. The CBE Manual for Authors, Editors, and Publishers, 6th edn. (Cambridge University Press, Cambridge), ISBN 0-521-47154-0.
1.5. Nomenclature
Only generic and chemical names of drugs should be used, although a proprietary equivalent may be indicated once, in parentheses. Pharmacological and Chemical Synonyms, E.E.J. Marler, 9th edn. (Elsevier, Amsterdam, 1990) may be consulted.
The nomenclature of chemical substances should be consistent, clear and unambiguous, and should conform to the usage of the American Chemical Society and the convention recommended by the International Union of Pure and Applied Chemistry (IUPAC). When in doubt, writers should consult the indexes of Chemical Abstracts; the various reports and pamphlets of the American Chemical Society Committee on Nomenclature, Spelling and Pronunciation; and from the International Union of Biochemistry and Molecular Biology (IUBMB): Biochemical Nomenclature and Related Documents (Portland Press, London).
When drugs, which are mixtures of stereoisomers are used, the fact that they have a composite nature and the implication of this for interpretation of the data and drawing of conclusions should be made clear. The use of the appropriate prefix is essential. Use of the generic name alone without prefix would be taken to refer to agents with no stereoisomers. The nomenclature of the various isomers and isomeric mixtures can be found in: (i) IUPAC, Nomenclature of Organic Chemistry, eds. J. Rigaudy and S.P. Klesney (Pergamon Press, London), 1979, p. 481; (ii) Signs of the times: the need for a stereochemically informative generic name system, Simonyi, M., J. Gal and B. Testa, 1989, Trends Pharmacol. Sci. 10, 349. For nomenclature of peptides, see Neuropeptides, Vol. 1, 1981, p. 231.
The nomenclature of receptors and their subtypes should conform to the TIPS 1995 Receptor & Ion Channel Nomenclature Supplement (Trends Pharmacol. Sci. Receptor Nomenclature Supplement 1995). Copies of this supplement are available from the publisher (Elsevier Trends Journals, Oxford Fulfilment Centre, P.O. Box 800, Kidlington, Oxford OX5 1DX, UK. Tel.: (44-1865) 843-699; Fax: (44-1865) 843-911).
The trivial name of the enzyme may be used in the text, but the systematic name and classification number according to Enzyme Nomenclature, rev. edn. (Academic Press, New York, NY, 1984) should be quoted the first time the enzyme is mentioned.
1.6. Editorial review All manuscripts are generally submitted to 2-3 referees who are chosen for their ability to evaluate the work. Supplementary material may be included to facilitate the review process. Accepted (but not yet printed) papers that are required for the review process should be provided in three copies for use by the referees. Authors may request that certain referees should not be chosen. Members of the editorial board will usually be called upon for advice when there is disagreement among the referees or between referees and authors, or when the editors believe that the manuscript has not received adequate consideration by the referees.
In order to reduce mailing costs, manuscripts will not be returned. Only the decision of the editorial office, together with the advice of the referees will be sent to the author(s). Referees will be requested to keep the copy of the manuscript which they have received for evaluation, but to destroy it once they have been notified of the final decision concerning the manuscript.
All referees' comments must be responded to, and suggested changes be made. The author should detail the changes made in response to the referees' comments and suggestions in an accompanying letter. If the author disagrees with some changes, the reason, supported by data, should be given. The editors may refuse to publish manuscripts from authors who persistently ignore referees' comments. Revised manuscripts should be returned in duplicate to the Editor-in-Chief. Handwritten additions or corrections will not be accepted. Only complete retyping of the pages affected by revision is acceptable. The final version of the manuscript should be submitted on disk (see section 1.3) together with two identical printed hard copies. A revised manuscript should be received by the editorial office not later than 1 month (in case of minor revision) or 4 months (in case of extensive revision) after the editorial decision was sent to the author(s); otherwise it will be processed as a new manuscript.
2. Organization and style of manuscripts
Authors should consult a current issue of the journal for the general manner of presentation. Manuscripts should be written in clear, concise English (see section 1.1), bearing in mind that English is not the native language of many of the readers. Terms that are not generally understood should be avoided; however if it is absolutely necessary to use such terms, they must be defined.
2.1. Research articles
2.1.1. General
The manuscript of a research article should be arranged as follows.
First page: title, surname(s) and full first name(s) of each author; name and address of the establishment where the work was done; name, full postal address, telephone and telefax numbers and e-mail of author to whom proofs and other correspondence should be sent. Next page: abstract and keywords (indexing terms, normally 3-6 items). Pages 3 to end: 1. Introduction; 2. Materials and methods; 3. Results; 4. Discussion; Acknowledgements; References; Tables; Figure legends and Figures. Parts 3 & 4 may be combined into one item: Results & Discussion. Subdivisions of a section should also be numbered within that section: 2.1., 2.2., 2.3., etc. All pages should be numbered consecutively, the title page being p. 1.
Supplementary material for electronic publication can be published on the journal website alongside the article. In the print version, a URL reference will be made to point readers to the location of the article and supplementary material.
2.1.2. Abstract and keywords
The abstract with keywords should be typed on a separate sheet. The abstract should include: the reason why the experiments were done, a very brief description of the experiments (including species, tissue, etc.), followed by the main results, and finally, a conclusion giving the relevance of the results to the question asked. The abstract must be completely self-explanatory. The abstract should not exceed approximately 200 words. No footnotes may be used and a reference, if cited, must be given in full. Standard terms and scientific nomenclature should be used. Abbreviations and contractions, except those for weights and measures and those explained, should not be used. Below the abstract, type 3-6 keywords or short phrases suitable for indexing. These terms will be printed at the end of the abstract. If possible, keywords should be selected from Index Medicus or Excerpta Medica Index.
2.1.3. Introduction, Materials and Methods, Results, Discussion
The introduction should not be an extensive review of the literature but should refer only to previous work which has a direct bearing on the topic to be discussed.
Materials and methods should be written clearly and in such detail that the work can be repeated by others. Procedural detail that has been published previously should be referred to by citation. When a modified procedure is used, only the author's modifications of the previously published method need to be given in detail.
Results should be described concisely. Text, tables and figures must be internally consistent.
The discussion should involve the significant findings presented. Wide digressions are unacceptable because of the limitations of space.
2.2. References
Authors are responsible for the accuracy and completeness of their references as these will not be checked by the editorial office.
References should be listed alphabetically (see sample references) according to the "Harvard" system. Articles written by the same first author with different second authors should be listed according to the second author's surname. Articles written by the same first author with more than one co-author should be listed alphabetically according to the first author's surname and then according to the year of publication. Two or more references to the same first author with the same publication year should have a, b, c, etc., suffixed to the year indicating the alphabetical order of the second or third author, etc.
References to journals should contain the names and initials of the author(s), the year, the full title, the abbreviation of the name of the periodical according to the List of Serial Title Word Abbreviations (available from the International Serials Data System, 20 Rue Bachaumont, 75002 Paris, France; ISBN 2-904938-02-8) followed by the volume and page numbers.
References to books should include the title and name and city of the publisher.
References in the text should be cited by the author's name and the year of publication. For 3 or more authors the name of the first author followed by et al. should be used, e.g., Davis, Robinson (1990) or (Davis, Illum, 1984; de Ber et al., 1988, 1989; Borchardt et al., 1990, 1991a,b,c).
Sample references
Periodicals:
Fagerholm, U., Lennernas, H., 1995. Experimental estimation of the effective unstirred water layer thickness in the human jejunum and its importance in oral drug absorption. Eur. J. Pharm. Sci. 3, 247-253.
Lipinski, C.A., Lombardo, F., Dominy, B.W., Feeney, P.J., 1997. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug. Deliv. Rev. 23, 3-25.
Books:
Alderborn, G., Nystrom, C., 1998. Pharmaceutical Powder Compaction Technology. Marcel Dekker, New York.
Kissel, T., Koneberg, R., 1996. Injectable biodegradable microspheres for vaccine delivery. In: Cohen, S. and Bernstein, H. (Eds.), Microparticulate systems for the delivery of proteins and vaccines. Marcel Dekker, New York, pp. 51-87.
Unpublished observations, personal communications and manuscripts in preparation or submitted for publication may be referred to in the text but should not appear in the list of references. Manuscripts in press (i.e., accepted for publication) may be included in the references; the name of the journal in which they are to appear must be given.
2.3. Illustrations
Either the original drawings plus 3 good photographs, or 4 good photographs of the drawings (on glossy paper unmounted) or 4 high-quality computer printouts should be submitted. Illustrations may be submitted in electronic format as well, but must always be accompanied by reproducible paper printouts. Photocopies may not be used instead of originals. The photographs should be of adequate definition and contrast. The number of illustrations should be limited to the essential.
(a) It is important to allow for reduction to fit a single column, 8.4 cm wide or at most a double column, maximally 17.6 cm wide. Of preference, illustrations, especially photomicrographs, should be submitted in their final size (single or double column). When possible, all key symbols should be explained in the figures. All letters and numerals appearing in a particular illustration should be of the same size (approximately 1.4-2.0 mm height when reduced to 8.4 cm width). Comparable illustrations should carry letters, figures and numerals of the same size when reduced to 8.4 cm width.
(b) Graphs should be prepared by a skilled photographer so that the dark, cross-hatched background is eliminated, the faint portions of the graphs are intensified, and a sharp print is obtained. This process may be avoided by using blue-ruled instead of black-ruled recording paper for the originals.
(c) Drawings of chemical structures should as far as possible be produced with the use of a drawing program such as ChemDraw. Authors using the current versions of ChemDraw, ChemIntosh and ChemWindows should use the JOC format.
(d) A calibration bar should be drawn on the micrographs instead of giving a magnification factor in the figure legend.
(e) All illustrations should be referred to as figures and numbered in Arabic numerals (Fig. 1, 2, etc.).
(f) Legends to figures should make the figures comprehensible without reference to the text.
(g) Colour reproduction of illustrations is available at cost but in some cases may be waived at the discretion of the Editor-in-Chief. The 2003 price for colour figures is 272 Euro for the first page and 182 Euro for subsequent pages. Original high-quality illustrations (preferably slides) should be well protected against possible damage during shipment. Detailed information regarding the use of colour may be obtained from the publisher at the time of submission of the manuscript to the editors.
2.4. Tables
Tables should be prepared for use in a single column (8.4 cm wide) or be of page width (17.6 cm).
(a) Each table should have a brief explanatory heading and sufficient experimental detail (following the table body as a footnote) so as to be intelligible without reference to the text.
(b) Tables should not duplicate material in text or illustrations.
(c) Short or abbreviated column headings should be used and, if necessary, explained in footnotes, and indicated as a, b, c, etc.
(d) Statistical measures of variation, S.D., S.E., etc. should be identified.
(e) Tables should be numbered separately in Arabic numerals (Table 1, 2, etc.).
2.5. Formulas and equations
Structural chemical formulas, process flow diagrams and complicated mathematical expressions should be very clearly presented. All subscripts, superscripts, Greek letters and unusual characters must be identified. Structural chemical formulas and process flow diagrams should be prepared in the same way as graphs.
2.6. Review articles
One page suggestions for comprehensive reviews should be sent to the Editor-in-Chief for consideration.
The manuscript of a review article should be arranged as described for research articles (see sections 2.1 - 2.5) but according to the following sections: title page, abstract and keywords (indexing terms, normally 3-6 items), Introduction, Specific sections determined by the author, Conclusions, Acknowledgements, References, Figure legends and Figures, Tables. Sections ranging from the Introduction to the Conclusions should be numbered. Subdivisions within a section should also be numbered within that section: 2.1., 2.2., 2.3. etc. All pages should be numbered consecutively, the title page being p.1.
2.7. Commentaries and Mini-reviews
One page suggestions for commentaries and mini-reviews should be sent directly to the Editor-in-Chief for consideration. Please see detailed information on commentaries and mini-reviews below.
2.7.1 Commentaries (Guidance)
The definition of a Commentary for EJPS is three-fold. Firstly, it can be an argued piece of provocative scientific writing purporting to take a balanced position on a controversial pharmaceutical science topic. A second option is for the author to approach the topic from a particular viewpoint on one side of an argument. A third option is to provide a topical update on a hot topic in Pharmaceutical Sciences and this can be more informative than controversial.
Commentaries will be commissioned by the editors in advance or invited from non-commissioned authors if they wish to initially submit a one page summary of the intended Commentary to the editors in advance. All manuscripts will be assessed by 2-3 independent referees.
The journal is looking for a stimulating and provoking essays, with referenced material, but without an extensive reference list. Commentaries can contain one summary figure and / or table and should have no more than 30 references to preferably recent peer-reviewed material. The word count should be approximately 2,000 words maximum.
The commentary should have short abstract summary of 150 to 200 words and 4-5 key words should be included. The text should be broken down into 4-5 numbered sections beginning with an Introduction and ending with a Conclusions section. A model of the structure is to be found in Eur.J.Pharm.Sci., 8, (1999) 161-165 by K. L. Audus.
2.7.2 Mini-review (Guidance)
Mini-reviews are thought provoking reviews of contemporary pharmaceutical research. Themes are as described in the Scope of the Journal section.
Mini-reviews will usually be commissioned by the editors in advance, but contributions are invited from non-commissioned authors if they wish to initially submit a one page summary of the intended review to the editors in advance. All manuscripts will be assessed by 2-3 independent referees.
The structure of the mini-review is as follows: a title page followed by a 200-300 word abstract with 4-5 key words. The text is then divided into numbered sections finishing with a Summary section. References should be kept to a maximum of 60 and should be mostly to recent peer-reviewed material. There is a combined maximum of 5 figures / tables. Authors are encouraged to submit their original unpublished work as part of the review if appropriate. The total length of the review should be a maximum of 4,000 words.
3. Copyright regulations for authors
Upon acceptance of an article by the Journal, author(s) will be asked to transfer the copyright of the article to the publisher. This transfer will ensure the widest possible dissemination of information.
4. Correcting proofs and reprints
Elsevier Science is now sending PDF proofs to authors by e-mail for correction. If an author is unable to handle this process, regular print proofs will be sent. Elsevier Science will do everything possible to get the article corrected and published as quickly and accurately as possible. Therefore, it is important to ensure that all corrections are sent back in ONE communication. Subsequent corrections will not be possible. Only typesetting errors may be corrected; no changes in, or additions to, the accepted manuscript will be allowed. Proofs should be returned to Elsevier Science within 48 hours.
EJPS has no page charges. Twenty-five offprints of each paper will be supplied free of charge to the principal author. Additional offprints can be ordered at prices shown on the offprint order form that accompanies the galley proofs.
5. Author enquiries
All questions arising after acceptance of a manuscript by the Editors, especially those relating to proofs, publication and reprints, should be directed to the Publisher.
Elsevier Science Ireland Ltd
Brookvale Plaza
East Park
Shannon, Co. Clare
Ireland
Tel: +353 61 709600
Fax: +353 61 709100
E-mail: authorsupport@elsevier.com
Please visit the Elsevier Science Author Gateway at http://authors.elsevier.com to track accepted articles and set up e-mail alerts to inform you of when the article status has changed. Information on artwork guidelines, copyright information, and frequently asked questions is also available.
No responsibility is assumed by the Publisher for any injury and/or damage to persons or property as a matter of products liability, negligence or otherwise, or from any use or operation of any methods, products, instructions or ideas contained in the material herein. Because of the rapid advances made in the medical sciences, independent verification of diagnoses and drug dosages should be made.
Editorial Board
Editor-in-Chief:
A. Urtti, University of Kuopio, Department of Pharmaceutics, P.O. Box 1627, FIN-70211 Kuopio, Finland, E-mail: ejps@uku.fi
Section Editors:
S. Auriola, University of Kuopio, Finland
S. Frøkjaer, Royal Danish School of Pharmacy, Copenhagen, Denmark
A. Hallberg, Uppsala University, Sweden
K. Järvinen, University of Kuopio, Finland
H.G. Kristensen, Royal Danish School of Pharmacy, Copenhagen, Denmark
M. Lang, Uppsala University, Sweden
D.K.F. Meijer, University of Groningen, The Netherlands
J. Mönkkönen, University of Kuopio, Finland
Associate Editors: (for Commentaries and Mini-Reviews)
H. Bräuner-Osborne, Royal Danish School of Pharmacy, Copenhagen, Denmark
P. York, University of Bradford, Bradford, UK
Editorial Board: L. Aarons, University of Manchester, UK
M.J. Alonso, University of Santiago, Santiago de Compostela, Spain
C. Altomare, University of Bari, Bari, Italy
G. Amidon, University of Michigan, Ann Arbor, MI, USA
P. Artursson, Uppsala University, Sweden
Y. Baba, University of Tokushima, Japan
J.-P. Behr, Faculte de Pharmacie de Strasbourg, Illkirch, France
O.J. Bjerrum, Danish School of Pharmacy, Copenhagen, Denmark
H. Blume, Eschborn, Germany
R.T. Borchardt, University of Kansas, Lawrence, KS, USA
M. Brandl, University of TromsØ, TromsØ, Norway
D. Braydon, University College, Dublin, Ireland
G. Buckton, University of London, UK
C.M. Caramella, University of Pavia, Pavia, Italy
P. Colombo, University of Parma, Italy
D.J.A. Crommelin, Utrecht University, The Netherlands
M. Danhof, Leiden University, The Netherlands
M.C. Davies, University of Nottingham, Nottingham, UK
H. Derendorf, University of Florida, Gainesville, FL, USA
P.J. Dressman, J.W. Goethe University, Frankfurt am Main, Germany
M. Eichelbaum, Dr. Margarete Fischer-Bosch Institute, Stuttgart, Germany
E. Fattal, School of Pharmacy, University of Paris Sud, Chatenay-Malabry, France
G. Folkers, ETH Zurich, Switzerland
G. Golomb, The Hebrew University of Jerusalem, Jeruslem, Israel
R. Gurny, University of Geneva, Switzerland
R.C. Hider, King's College London, London, UK
J. Hirronen, University of Helsinki, Helsinki, Finland
N. Holford, University of Auckland, New Zealand
B. Houston, University of Manchester, UK
L. Illum, DanBioSyst UK Ltd., Nottingham, UK
K. Inui, Kyoto, Japan
H. Junginger, Gorlaeus Laboratories, Leiden, The Netherlands
M. Karlsson, Uppsala University, Sweden
T. Katamaki, Hokkaido University, Hokkaido, Japan
T. Kissel, Philipps University Marburg, Germany
J. Kopecek, University of Utah, Salt Lake City, USA
R. Kostiainen, University of Helsinki, Helsinki, Finland
J. Kreuter, J.W. Goethe University, Frankfurt, Germany
P. Krogsgaard-Larsen, Royal Danish School of Pharmacy, Copenhagen, Denmark
R.S. Langer, Massachusetts Institute of Technology, Cambridge, USA
V.H.L. Lee, University of Southern California, Los Angeles, CA, USA
C.-M. Lehr, University of Saarland, Saarbrucken, Germany
H. Lennernäs, Uppsala University, Sweden
H. Leuenberger, University of Basel, Switzerland
P. Macheras, University of Athens, Greece
J.W.K. McGinity, University of Texas at Austin, Austin, USA
R. Middaugh, The University of Kansas, Lawrence, USA
R.H. M¨¹ller, Free University Berlin, Germany
G. Molema, Groningen University Institute of Drug Expl., Groningen, The Netherlands
O. Pelkonen, University of Oulu, Finland
F. Podczeck, Sunderland University, UK
R.J. Quinn, Griffith University, Brisbane, Australia
J.P. Remon, University of Gent, Belgium
R. Rowe, Zeneca Pharmaceuticals, Macclesfield, UK
W. Sad¨¦e, Ohio State University, Columbus, OH, USA
E.H.T. Schacht, Ghent University, Ghent, Belgium
W. Schunack, Free University Berlin, Germany
C. Selch-Larsen, Royal Danish School of Pharmacy, Copenhagen, Denmark
S. Severin, I.M. Sechnov's Moscow Med. Acad., Moscow
L. Sheiner, University of California, San Francisco, CA, USA
S. Spampinato, University of Bologna, Italy
G. Storm, University of Utrecht, Utrecht, The Netherlands
Y. Sugiyama, University of Tokyo, Tokyo, Japan
F. Szoka, University of California, San Francisco, CA, USA
Y. Takakura, Kyoto University, Kyoto, Japan
G. Tucker, Royal Hallamshire Hospital, Sheffield, UK
K. Uekama, Kumamoto University, Japan
K. Ulbrich, Chem. Academy of Sciences of the Czech Republic, Prague, Czech Republic
E. Walter, ETH Z¨¹rich, Z¨¹rich, Switzerland
|
